Sugi Predict

Sugi Predict / Compounds / SCHEMBL10242855

SCHEMBL10242855

SCHEMBL10242855

CC1=CS(=O)(=O)c2ccccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 2/20 0.50
▸ CA9 Q16790 2/20 0.50
▸ CA1 P00915 1/20 0.50
▸ MAPT P10636 5/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ LMNA P02545 3/20 0.47
▸ TP53 P04637 2/20 0.47
▸ HTT P42858 2/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ GPR3 P46089 1/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ MEN1 O00255 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ CYP1A2 P05177 3/20 0.43
▸ CYP2C9 P11712 3/20 0.43
▸ CYP2C19 P33261 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31009842 1.00 CA2 (0.50) CA2CA9CA1MAPTKMT2A
SCHEMBL8024080 0.77 GPR3 (0.46) CA2CA9CA1MAPTKMT2A
SCHEMBL18805433 0.77 CA1 (0.50) CA2CA9CA1MAPTKMT2A
SCHEMBL23029879 0.74 CA1 (0.47) CA2CA9CA1MAPTKMT2A
SCHEMBL17121934 0.73 GPR3 (0.46) CA2CA9CA1MAPTKMT2A
SCHEMBL21032218 0.73 GPR3 (0.46) CA2CA9CA1MAPTKMT2A
SCHEMBL6337534 0.73 GPR3 (0.46) CA2CA9CA1MAPTKMT2A
SCHEMBL8178818 0.73 GPR3 (0.46) CA2CA9CA1MAPTKMT2A
SCHEMBL10860632 0.73 GPR3 (0.46) CA2CA9CA1MAPTKMT2A
SCHEMBL13394752 0.72 KDM4E (0.51) CA2CA9MAPTKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112430228-B Chiral 2, 3-dihydrobenzo [ b ] thiophene 1, 1-dioxide, derivative and preparation method 四川大学 2021-09-07 — — CN claimed
US-12583870-B2 Azaheteroaryl compound and application thereof SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) 2026-03-24 — — US disclosed
US-20230002414-A1 AZAHETEROARYL COMPOUND AND APPLICATION THEREOF SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) 2023-01-05 — — US disclosed
EP-3489233-B1 INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) 2022-01-12 — — EP disclosed
CN-112430228-B Chiral 2, 3-dihydrobenzo [ b ] thiophene 1, 1-dioxide, derivative and preparation method 四川大学 2021-09-07 — — CN disclosed
EP-3328832-B1 FUCOSIDASE INHIBITORS HORIZON ORPHAN LLC (US) 2021-03-03 — — EP disclosed
CN-112430228-A Chiral 2, 3-dihydrobenzo [ b ] thiophene 1, 1-dioxide, derivative and preparation method 四川大学 2021-03-02 — — CN disclosed
US-10800765-B2 Indole derivative used as CRTH2 inhibitor CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2020-10-13 — — US disclosed
US-20190248770-A1 INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2019-08-15 — — US disclosed
US-10308607-B2 Fucosidase inhibitors HORIZON ORPHAN LLC (US) 2019-06-04 — — US disclosed
US-20170125691-A1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2017-05-04 — — US disclosed
US-20170125691-A1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2017-05-04 — — US disclosed
US-20170029376-A1 FUCOSIDASE INHIBITORS RAPTOR PHARMACEUTICALS INC. (US) 2017-02-02 — — US disclosed
WO-2017019925-A1 FUCOSIDASE INHIBITORS RAPTOR PHARMACEUTICALS INC. (US) 2017-02-02 — — WO disclosed
US-20140221383-A1 CETP INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-08-07 — — US disclosed
US-8735435-B2 CETP inhibitors MERCK SHARP & DOHME CORP. (US) 2014-05-27 — — US disclosed
EP-2415759-A1 CETP inhibitors Merck Sharp & Dohme Corporation (US) 2012-02-08 — — EP disclosed
US-7449500-B2 Ink jet ink containing multimetallic polymeric colorants EASTMAN KODAK COMPANY (US) 2008-11-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221383-A1 CETP INHIBITORS CETP, APOB, MTTP CA2 4174/4885CA9 4045/4885CA1 4795/4885
US-20230002414-A1 AZAHETEROARYL COMPOUND AND APPLICATION THEREOF EZH2, EED, SUZ12 CA2 3791/4885CA9 3487/4885CA1 2887/4885
US-12583870-B2 Azaheteroaryl compound and application thereof NR3C1, EED, EZH2 CA2 2249/4885CA9 1820/4885CA1 832/4885
US-20170029376-A1 FUCOSIDASE INHIBITORS FUCA1, FUCA2, ENGASE CA2 3803/4885CA9 774/4885CA1 1346/4885
US-20190248770-A1 INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR NR3C2, CRHR2, TPH2 CA2 1032/4885CA9 2710/4885CA1 2773/4885
US-10800765-B2 Indole derivative used as CRTH2 inhibitor NR3C2, CRHR2, TPH2 CA2 1032/4885CA9 2710/4885CA1 2773/4885
US-10308607-B2 Fucosidase inhibitors FUCA1, FUCA2, ENGASE CA2 3803/4885CA9 774/4885CA1 1346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.